ScreenerHero

HPHA Heidelberg Pharma AG

XETRA · DE · Healthcare · Biotechnology · heidelberg-pharma.com
2.350EUR0.00%Mkt Cap: 119.50M $P/E: —

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candid…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap119.50M USD
Enterprise Value92.46M USD
Revenue (TTM)8.09M USD
Gross Profit1.29M USD
Net Income (TTM)-45.96M USD
Revenue/Share0.16 EUR
Last Price2.350 EUR
Fiscal Year EndNov 2025
MR QuarterMay 2026
Employees41
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A11QVV0
Valuation
P/E (Trailing)—
P/E (Forward)-4.68
PEG5.46
EV/EBITDA-2.31
EV/Revenue11.42
P/S14.77
P/B-7.73
EPS (TTM)-0.71
EPS (Forward)-0.50
52W Range
2.24010% of range3.340
52W High3.340 EUR
52W Low2.240 EUR
Profitability
Gross Margin81.31%
Oper. Margin3.32%
EBITDA Margin0.00%
Profit Margin-2901.15%
ROE387.26%
ROA-110.87%
Growth
Revenue Growth3566.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-34.35M USD
CapEx (TTM)146.79K USD
FCF Margin-253.46%
FCF Yield-17.16%
Net Debt-27.05M USD
Net Debt/EBITDA0.68
Balance Sheet
Debt/Equity-0.01
Current Ratio5.29
Quick Ratio3.78
Book Value/Sh-0.30 EUR
Cash/Share0.53 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateJul 18, 2014
Analyst Consensus
Rating—
Target (Mean)6.750 EUR
Upside (mean)+187.2%
Target Range5.500 EUR – 8.000 EUR
5.500+187.2% to mean8.000
# Analysts2
Ownership
Shares Out.46.78M
Float9.97M
Insiders79.00%
Institutions1.73%
Technical
SMA 502.517 (-6.6%)
SMA 2002.743 (-14.3%)
Beta0.77
S&P 52W Chg14.58%
Avg Vol (30d)4.29K
Avg Vol (10d)8.37K
Technical Indicators
RSI (14)37.9
MACD-0.0279
MACD Signal-0.0092
MACD Hist.-0.0186
BB Upper2.641 EUR
BB Middle2.495 EUR
BB Lower2.350 EUR
BB Width11.66%
ATR (14)0.1196 EUR
Vol Ratio (20d)1.40x